Texas
LATEST FROM BIOSPACE
Houston-based money manager Alan Eisenman testified in the ongoing Elizabeth Holmes fraud trial that he sought “straight answers” about the company’s work for several years.
Vaxxinity set its initial public offering price at $13 per share, raising $76 million. The company was launched in April via consolidation of the vaccine development efforts of COVAXX and United Neuroscience.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
A new study was published this week and proposed a potential new biomarker for predetermining patient responsiveness to immune checkpoint blockade therapy.
Yet another busy week for clinical trial news. Here’s a look.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Broad announced that it is bringing René Salazar on board as its first chief equity officer.
PRESS RELEASES